The Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reiterated at Royal Bank Of Canada

The Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research note published on Monday morning, StockTargetPrices.com reports. The firm currently has a C$38.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts also recently weighed in on the company. Scotiabank reaffirmed a sector perform rating and set a C$17.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 11th. Morgan Stanley downgraded Valeant Pharmaceuticals Intl from an overweight rating to an equal weight rating in a research note on Thursday, December 15th. Finally, TD Securities reduced their target price on Valeant Pharmaceuticals Intl from C$38.50 to C$18.00 and set a hold rating for the company in a research note on Thursday, November 10th.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 19.86 on Monday. The company’s market capitalization is $6.90 billion. The firm has a 50-day moving average of $19.92 and a 200 day moving average of $28.35. Valeant Pharmaceuticals Intl has a one year low of $17.42 and a one year high of $142.35.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Related posts

Leave a Comment